Navigation Links
Receptos to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference
Date:8/13/2012

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 9:10 a.m. EDT on Wednesday, August 15, 2012, at the Le Parker Meridien Hotel in New York City. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its Phase 2 clinical development programs for multiple sclerosis and inflammatory bowel disease with RPC1063.

About RPC1063 and S1P1 Agonists
RPC1063 is a novel, differentiated sphingosine 1-phosphate 1 receptor (S1P1) selective agonist exhibiting picomolar potency that is effective in rodent models of both multiple sclerosis (MS) and inflammatory bowel disease (IBD), and possesses an excellent safety profile in non-clinical toxicology studies. Receptos has completed a Phase 1 clinical safety study with RPC1063 under a US IND that supports the desired differentiation profile and establishes justification for initiation of MS and IBD clinical efficacy trials in 2012. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In autoimmune disorders, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying cause of disease.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information - driven drug discovery, including GPCR structure determination. The company's lead program, RPC1063, is a best-in-class S1P1 small molecule agonist candidate for autoimmune indications. Receptos' expertise in S1P1 biology has been informed by the company's high resolution protein crystal structure of the S1P1 receptor, published in Science earlier this year. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271
Ian.stone@russopartnersllc.com
David.schull@russopartnersllc.com 


'/>"/>
SOURCE Receptos Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
2. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
3. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
4. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
6. Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference
7. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
8. Cepheid to Webcast Upcoming Financial Presentations
9. Isis Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. STAAR Surgical To Present At The 32nd Annual Canaccord Growth Conference
11. Solta Medical to Present at the 32nd Annual Canaccord Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
Breaking Medicine News(10 mins):